Interne link ProQR Doses First Patient in Phase 2/3 ILLUMINATE Trial of Sepofarsen for LCA10 april 15, 2019 om 11:00 AM UTC
Interne link ProQR to Present at the H.C. Wainwright Global Life Sciences Conference april 01, 2019 om 11:00 AM UTC
Interne link ProQR spins out all Dystrophic Epidermolysis Bullosa activities into newly formed Wings Therapeutics created by EB Research Partnership maart 26, 2019 om 08:01 PM UTC
Interne link ProQR traite le premier patient dans l’essai STELLAR de Phase 1/2 du QR-421a pour le syndrome d’Usher de type 2 maart 11, 2019 om 04:45 PM UTC
Interne link ProQR Doses First Patient in Phase 1/2 STELLAR Trial of QR-421a for Usher Syndrome Type 2 maart 11, 2019 om 12:00 PM UTC
Interne link ProQR Reports Fourth Quarter and Full Year 2018 Operating and Financial Results februari 27, 2019 om 12:00 PM UTC
Interne link ProQR Announces “ProQR Vision 2023” Strategy at its Annual R&D Day januari 29, 2019 om 01:30 PM UTC
Interne link ProQR Reaches Agreement with the FDA on Design of Phase 2/3 Pivotal Trial for Sepofarsen (QR-110) for Leber’s Congenital Amaurosis 10 januari 07, 2019 om 12:00 PM UTC
Interne link ProQR Receives Fast Track Designation from FDA for QR-421a for Usher Syndrome Type 2 januari 02, 2019 om 12:00 PM UTC
Interne link ProQR Therapeutics Added to NASDAQ Biotechnology Index december 24, 2018 om 12:00 PM UTC
Interne link ProQR annonce la publication dans Nature Medicine des données du QR-110 pour l’amaurose congénitale de Leber 10 december 18, 2018 om 03:27 PM UTC
Interne link ProQR Announces Publication in Nature Medicine of QR-110 Data for Leber’s Congenital Amaurosis 10 december 17, 2018 om 04:52 PM UTC
Interne link ProQR Announces Strategic Changes to the Management Team and Key New Hires december 13, 2018 om 12:00 PM UTC
Interne link ProQR Receives € 4.7 million in Innovation Credit from Dutch Government for QR-110 for LCA10 december 10, 2018 om 12:00 PM UTC
Interne link ProQR Announces Clearance of IND to Start Clinical Trial of QR-421a in Usher Syndrome Type 2 Patients december 04, 2018 om 12:00 PM UTC
Interne link ProQR to Present at the Evercore ISI HealthConX Conference november 20, 2018 om 12:00 PM UTC
Interne link ProQR Announces Financial Results for the Third Quarter of 2018 november 07, 2018 om 12:00 PM UTC
Interne link ProQR Announces Presentations at the European Oligonucleotide and Peptide Therapeutics Conference oktober 31, 2018 om 11:00 AM UTC
Interne link ProQR lizenziert weltweite Rechte für Arzneimittelkandidaten für die Augenheilkunde von Ionis Pharmaceuticals oktober 30, 2018 om 10:15 PM UTC
Interne link ProQR In-licenses Worldwide Rights to Ophthalmology Drug Candidate from Ionis Pharmaceuticals oktober 29, 2018 om 11:33 AM UTC
Interne link ProQR to Present at the Chardan Genetic Medicines Conference oktober 02, 2018 om 11:00 AM UTC
Interne link ProQR Announces Presentations at the OTS Annual Meeting september 24, 2018 om 11:00 AM UTC
Interne link ProQR Announces Closing of Underwritten Public Offering of Ordinary Shares with Full Exercise of Underwriters’ Option to Purchase Additional Shares september 11, 2018 om 08:01 PM UTC